

Press Release

New e-Learning Module in the Lonza QC Insider™ Toolbox Helps Scientists Overcome Interference in the Bacterial Endotoxins Test

Walkersville, MD, USA / Cologne, Germany, 12 July 2016 – Today Lonza announced the release of a new e-Learning Module for its QC Insider™ Toolbox, “Overcoming Interference,” which covers the causes of interference in the Bacterial Endotoxins Test (BET) and provides the user with solutions to help ensure compliance. Being able to overcome the inhibitory or enhancing properties of a sample is required by the BET monograph, the validation of which forms part of the test for the final product release of injectable drugs and medical devices. Many of the pharmaceutical products that are either in use or being developed today have characteristics that cause them to interfere with the BET.

Katrin Hoeck, Head of Marketing Analysis and Testing at Lonza Bioscience Solutions explains: “Some components of a test solution can interfere with the BET assay. Pre-treatment of samples is an important aspect in overcoming interference as a simple dilution will usually solve the issue; however, our new e-Learning Module helps QC professionals respond to situations when dilution alone is not sufficient to overcome interference.”

The e-Learning Modules, launched in January 2016 as part of the QC Insider™ Toolbox, are a suite of online endotoxin training courses designed to deliver the technical knowledge that Quality Control professionals need to achieve success with BET. Each interactive module can be taken at the user’s convenience; and, upon completion of a Knowledge Test, the learner will receive a Certificate of Completion for their training records.

More information is available by visiting: www.lonza.com/elearning

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
www.lonza.com

Press Release

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Cologne GmbH
Manager Marketing
Communications

Petra Haberkamm
Tel +49 221 991990
Fax +49 221 99199498
marcom.lbs@lonza.com

Lonza Group Ltd
Head Corporate
Communications

Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9540
dominik.werner@lonza.com

Lonza Group Ltd
Head External
Communications

Constance Ward
Tel +41 61 316 8840
Fax +41 61 316 9840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.